Kits Eyecare (TSE:KITS) Posts Quarterly Earnings Results

Kits Eyecare (TSE:KITS) posted its quarterly earnings results on Wednesday. The company reported C$0.04 EPS for the quarter, FiscalAI reports. The company had revenue of C$58.43 million during the quarter.

Here are the key takeaways from Kits Eyecare’s conference call:

• Q2 revenue rose 17.8% year over year to CAD 58.4 million, while net income improved to CAD 1.5 million from a prior-year loss and operating cash flow reached a record CAD 7.8 million.
• The glasses business continued to accelerate, with revenue up 54%, delivered pairs up 32.4%, and premium lens upgrades reaching 45.2% of glasses revenue. Management said stronger first-order values, cross-selling, and repeat purchases are producing increasingly attractive customer cohorts.
• Kits ended the quarter with CAD 27.4 million in cash, no debt, and approximately CAD 42.4 million of accessible liquidity, while repurchasing CAD 1 million of shares. Gross margin expanded 160 basis points to 37.9%, and the company maintained its 15th consecutive quarter of positive Adjusted EBITDA.
• Management plans to rebalance marketing in the second half, maintaining glasses momentum while directing more acquisition spending toward contact lenses. Q3 guidance calls for revenue of CAD 62 million-CAD 64 million and an Adjusted EBITDA margin of 4%-6%, with near-term profitability potentially constrained by customer-acquisition investment and fulfillment costs.
• The Toronto flagship store launched near the end of Q2 and reportedly exceeded early expectations, with management citing stronger brand searches and a digital “halo” effect. Kits is considering a thoughtful expansion that could include approximately two additional locations in the second half of 2026.

Kits Eyecare Stock Performance

Shares of KITS traded down C$0.36 during mid-day trading on Thursday, reaching C$14.07. The stock had a trading volume of 17,416 shares, compared to its average volume of 117,818. The company has a fifty day moving average of C$13.59. The stock has a market capitalization of C$478.31 million, a price-to-earnings ratio of 140.70 and a beta of 0.06. Kits Eyecare has a 52-week low of C$10.61 and a 52-week high of C$22.56.

Insider Buying and Selling at Kits Eyecare

In other news, insider Joseph Thompson sold 75,000 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of C$13.65, for a total transaction of C$1,023,750.00. Following the sale, the insider owned 960,114 shares of the company’s stock, valued at approximately C$13,105,556.10. This represents a 7.25% decrease in their ownership of the stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. ATB Cormark Capital Markets decreased their target price on shares of Kits Eyecare from C$20.00 to C$16.75 and set a “speculative buy” rating for the company in a research report on Thursday, May 7th. Canaccord Genuity Group lowered their target price on shares of Kits Eyecare from C$23.00 to C$22.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Desjardins cut their price target on shares of Kits Eyecare from C$25.00 to C$23.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Stifel Nicolaus lowered their price objective on shares of Kits Eyecare from C$24.00 to C$21.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of C$20.69.

Kits Eyecare Company Profile

KITS (TSX: KITS) is one of the world’s fastest growing eyecare providers, offering high-quality, affordable prescription glasses and contact lenses through its vertically integrated digital platform. With advanced in-house lens manufacturing, an industry-leading digital fit experience powered by OpticianAI, and thousands of 5-star customer reviews, KITS is redefining how Canadians experience eyecare. Designed in Canada. Delivered worldwide.